Evidence map›Paper›PMID 37539163›Full record

ArticleHeliyon2023

Corrigendum to "The novel putative methyltransferase METTL7A as one prognostic biomarker potentially associated with immune infiltration in human renal cancer".

Zhiqian Yang, Wei Zhang, Lintai Li, Nan Hu, Xiangnan Dong, Yumei Chen, Wanxia Cai, Lianghong Yin, Fanna Liu, Donge Tang and 1 more

Open access · goldAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Zhiqian YangDepartment of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Wei ZhangClinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen 518020, China.
Lintai LiClinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen 518020, China.
Nan HuKey Renal Laboratory of Shenzhen, Department of Nephrology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, Shenzhen 518020, China.
Xiangnan DongDepartment of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Yumei ChenClinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen 518020, China.
Wanxia CaiClinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen 518020, China.
Lianghong YinDepartment of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Fanna LiuDepartment of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Donge TangClinical Medical Research Center, The Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen 518020, China.
Yong DaiDepartment of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.
Jinan University · CNFirst Affiliated Hospital of Jinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.1016/j.heliyon.2023.e15371.].

Identifiers

PMID37539163
PMCPMC10394904
OpenAlexW4379743168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.